VKTX — Viking Therapeutics, Inc.
$24.40-5.54%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for VKTX in the TickerWise workspace.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 45
- Website: https://www.vikingtherapeutics.com
Latest SEC filings for VKTX
Latest VKTX news
- Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market Read article
- NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains? Read article
- Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 Years Read article
- Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. Read article
- Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know Read article
- Viking Therapeutics Starts Phase III Development of Obesity Pill Read article
- Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? Read article
- Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.